Edition:
India

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

7.70USD
1:30am IST
Change (% chg)

$-0.15 (-1.91%)
Prev Close
$7.85
Open
$7.85
Day's High
$7.95
Day's Low
$7.70
Volume
4,595
Avg. Vol
20,347
52-wk High
$9.10
52-wk Low
$2.15

Chart for

About

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $54.00
Shares Outstanding(Mil.): 18.00
Dividend: --
Yield (%): --

Financials

BRIEF-Xenon Pharmaceuticals Q1 Net Loss Per Common Share $0.21

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co

* XENON PHARMACEUTICALS INC - ON MAY 8, CO ENTERED INTO AN AT--MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & COMPANY - SEC FILING

09 May 2018

BRIEF-Xenon Pharmaceuticals To Host Conference Call To Discuss Q1 2018 Financial Results

* XENON PHARMACEUTICALS TO HOST CONFERENCE CALL AND WEBCAST TO DISCUSS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement

* XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 Mar 2018

BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial

* XENON PHARMACEUTICALS ADVANCES SECOND PROPRIETARY EPILEPSY PRODUCT INTO THE CLINIC WITH INITIATION OF XEN901 PHASE 1 CLINICAL TRIAL Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

20 Feb 2018

BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year

* XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR

08 Jan 2018

Earnings vs. Estimates